Atherothrombotic complications are the main cause of mortality in subjects with diabetes.
Premature atherosclerosis, increased platelet reactivity and activation of coagulation factors …

Abstract Background and Aims Ezetimibe reduces plasma low-density lipoprotein
cholesterol (LDL-C) levels by up to 20%. However, its effect on plasma lipoprotein (a)[Lp (a)] …

Recent data from genetic and epidemiological studies strongly support a causal relationship
between elevated lipoprotein (a)[Lp (a)] concentrations and the development of …

Tissue factor (TF) is known to be the key element in the initiation of the extrinsic pathway of
the coagulation cascade and appears to be a critical determinant of atherosclerotic plaque …

The aim of this study was to assess the strength of hemostatic effects of ezetimibe,
administered alone or in combination with simvastatin, in patients with isolated …

Background and aims Statins might exert atheroprotective effects through lowering the pro-
atherogenic amino acid homocysteine. We conducted an updated systematic review and …

High levels of cholesterol and other lipid constituents are major risk factors in the
development of atherosclerosis as well as diseases and disorders associated with it …

In addition to the modification of the lipid profile, most lipid-lowering agents appear to
modulate other atherogenic pathways. We summarize the effects of lipid-lowering agents on …

Background Venous thromboembolism (VTE) has been shown to be associated with
inflammation. Statins that might reduce VTE risk have been found to exert anti-inflammatory …

Objectives: To compare lipid-lowering efficacy and high sensitive C-reactive protein
(hsCRP) level between morning and evening simvastatin administration in hyperlipidemia …